Gaithersburg-based Viela Bio Inc. has landed a $220 million agreement that will allow Chinese pharmaceutical company Hansoh Pharmaceutical Group Co. Ltd. to commercialize Viela’s lead candidate in China. The strategic partnership will give Hansoh the green light to develop and take to market inebilizumab, Viela’s product for blood cancers and autoimmune diseases. Earlier this month Viela met primary and secondary endpoints in a study for patients with neuromyelitis optica spectrum disorder, a…
from https://www.bizjournals.com/baltimore/news/2019/05/28/gaithersburg-s-viela-bio-strikes-220m-deal-with.html?ana=RSS&s=article_search
via https://baltimorecheckbook.tumblr.com/post/185204319272
No comments:
Post a Comment